<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess the efficacy of multiple treatment of phosphatidylinositol-3-kinase (PI3K) inhibitor on autochthonous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> in phosphatase and tensin homologue (Pten)-deficient genetically engineered mouse <z:e sem="disease" ids="C1516211" disease_type="Experimental Model of Disease" abbrv="">cancer models</z:e> using a longitudinal magnetic resonance imaging (MRI) protocol </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Using 3D MRI, B-cell follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> growth was quantified in a Pten(+/-)Lkb1(+/hypo) mouse line, before, during and after repeated treatments with a PI3K inhibitor GDC-0941 (75 mg/kg) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Mean pre-treatment linear <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> rate was 16.5±12.8 mm(3)/week </plain></SENT>
<SENT sid="3" pm="."><plain>Repeated 28-day GDC-0941 administration, with 21 days 'off-treatment', induced average <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> regression of 41±7% </plain></SENT>
<SENT sid="4" pm="."><plain>Upon cessation of the second treatment (which was not permanently cytocidal), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> re-grew with an average linear growth rate of 40.1±15.5 mm(3)/week </plain></SENT>
<SENT sid="5" pm="."><plain>There was no evidence of chemoresistance </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: This protocol can accommodate complex dosing schedules, as well as combine different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies </plain></SENT>
<SENT sid="7" pm="."><plain>It reduces biological variability problems and resulted in a 10-fold reduction in mouse numbers compared with terminal assessment methods </plain></SENT>
<SENT sid="8" pm="."><plain>It is ideal for preclinical efficacy studies and for phenotyping molecularly characterized mouse models when investigating gene function </plain></SENT>
</text></document>